As of 2025-09-18, the EV/EBITDA ratio of Ocular Therapeutix Inc (OCUL) is -8.01. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCUL's latest enterprise value is 1,795.48 mil USD. OCUL's TTM EBITDA according to its financial statements is -224.19 mil USD. Dividing these 2 quantities gives us the above OCUL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.8x - 10.8x | 7.6x |
| Forward P/E multiples | 12.1x - 16.0x | 14.6x |
| Fair Price | (13.69) - (12.09) | (12.46) |
| Upside | -212.6% - -199.4% | -202.4% |
| Date | EV/EBITDA |
| 2025-09-17 | -8.28 |
| 2025-09-16 | -8.22 |
| 2025-09-15 | -8.30 |
| 2025-09-12 | -8.51 |
| 2025-09-11 | -8.48 |
| 2025-09-10 | -8.70 |
| 2025-09-09 | -8.47 |
| 2025-09-08 | -8.43 |
| 2025-09-05 | -9.12 |
| 2025-09-04 | -8.42 |
| 2025-09-03 | -8.61 |
| 2025-09-02 | -8.42 |
| 2025-08-29 | -8.04 |
| 2025-08-28 | -8.28 |
| 2025-08-27 | -8.13 |
| 2025-08-26 | -8.13 |
| 2025-08-25 | -7.78 |
| 2025-08-22 | -8.11 |
| 2025-08-21 | -7.98 |
| 2025-08-20 | -7.85 |
| 2025-08-19 | -7.99 |
| 2025-08-18 | -8.12 |
| 2025-08-15 | -8.36 |
| 2025-08-14 | -8.39 |
| 2025-08-13 | -8.27 |
| 2025-08-12 | -8.25 |
| 2025-08-11 | -8.32 |
| 2025-08-08 | -8.04 |
| 2025-08-07 | -8.11 |
| 2025-08-06 | -8.27 |
| 2025-08-05 | -7.88 |
| 2025-08-04 | -8.15 |
| 2025-08-01 | -7.82 |
| 2025-07-31 | -7.55 |
| 2025-07-30 | -7.62 |
| 2025-07-29 | -7.69 |
| 2025-07-28 | -7.94 |
| 2025-07-25 | -8.04 |
| 2025-07-24 | -7.82 |
| 2025-07-23 | -7.85 |
| 2025-07-22 | -7.53 |
| 2025-07-21 | -7.50 |
| 2025-07-18 | -7.36 |
| 2025-07-17 | -7.40 |
| 2025-07-16 | -7.30 |
| 2025-07-15 | -7.17 |
| 2025-07-14 | -7.31 |
| 2025-07-11 | -7.13 |
| 2025-07-10 | -7.17 |
| 2025-07-09 | -6.92 |